Clinical Trial Update: Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes [Phase 2]

View source ↗

Summary

Phase 2 study evaluating carboplatin and docetaxel followed by Epstein-Barr virus–specific cytotoxic T lymphocytes in nasopharyngeal carcinoma; the trial status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• DOCETAXEL (DOCETAXEL)
• Epstein-Barr virus cytotoxic T lymphocytes

Snippet

Sponsor: Baylor College of Medicine | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: COMPLETED